Agenus
NASDAQ: AGENLexington, US · Delaware corporation · 9 known investors
Agenus is a biotechnology company developing cancer immunotherapies, including its lead investigational combination of botensilimab (an anti-CTLA-4 antibody) and balstilimab (a PD-1 inhibitor), known as BOT+BAL. It provides access to these investigational medicines for cancer patients through pathways such as clinical trials, Named Patient Programs, and compassionate-use programs across multiple countries.
Founders & leadership
GA
Garo ArmenChairman & CEO, Co-founder
OB
Ozer BaysalExecutive
RS
Robert SteinExecutive
CK
Christine KlaskininExecutive
KV
Karen ValentineExecutive
SO
Steven O'DayinChief Medical Officer
RT
Robin TaylorinChief Commercial Officer
CW
Craig WinterinChief Information Officer
TM
Tracy Mazza ClementeChief People Officer
Board
BC
Brian CorveseBoard director
SM
TD
Tom DechaeneBoard director
Investors · 9
Advent Life SciencesLondon
Grazia Equity GmbHStuttgart · $540K – $2.7M
HEALTHCARE ROYALTY PARTNERSNew York
Oberland CapitalNew York · $50M – $300M
Commodore CapitalreportedNew York
InvusreportedNew York
Ligand PharmaceuticalsreportedJupiter · $10M – $50M
RA CapitalreportedBoston
Also in the syndicate · 1
TCGX
Funding
SEC filings, press & company announcements$281.2M disclosed across 9 rounds · 2015–2026
- $85Mprivate placementAug 2026 · 2 sources
Commodore Capital, Invus, Ligand Pharmaceuticals, RA Capital Management, TCGX
Source ↗
▶$30MraisedFeb 2019 · 1 investors · BiotechnologyRule 506(b)
▶$30MraisedFeb 2019 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Brian CorveseDirector
- Evan KearnsExecutive Officer
- Timothy R. WrightDirector
- Jennifer BuellExecutive Officer
- Ulf WiinbergDirector
- Ozer BaysalExecutive Officer
- Wadih JordanDirector
- Alex DuncanExecutive Officer
- Christine KlaskinExecutive Officer
- Allison Jeynes-EllisDirector
- Christian CortisExecutive Officer
- Garo H. ArmenExecutive Officer, Director
- Offering amount
- $30M
- Amount sold
- $30M
- First sale
- Jan 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$40MraisedOct 2018 · 2 investors · BiotechnologyRule 506(b)
▶$40MraisedOct 2018 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Timothy R. WrightDirector
- Garo H. ArmenExecutive Officer, Director
- Ozer BaysalExecutive Officer
- Brian CorveseDirector
- Christine KlaskinExecutive Officer
- Ulf WiinbergDirector
- Christian CortisExecutive Officer
- Alex DuncanExecutive Officer
- Evan KearnsExecutive Officer
- Wadih JordanDirector
- Jennifer BuellExecutive Officer
- Offering amount
- $40M
- Amount sold
- $40M
- First sale
- Oct 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$60MraisedMar 2017 · 1 investors · BiotechnologyRule 506(b)
▶$60MraisedMar 2017 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Karen H. ValentineExecutive Officer
- Christine M. KlaskinExecutive Officer
- Shahzad MalikDirector
- Robert B. SteinExecutive Officer
- Garo H. ArmenExecutive Officer, Director
- Timothy WrightDirector
- Ozer BaysalExecutive Officer
- Shalini SharpDirector
- Wadih JordanDirector
- Ulf WiinbergDirector
- Brian CorveseDirector
- Offering amount
- $60M
- Amount sold
- $60M
- First sale
- Feb 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$500KraisedJan 2016 · 1 investors · BiotechnologyRule 506(b)
▶$500KraisedJan 2016 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Timothy R. WrightDirector
- Garo ArmenExecutive Officer, Director
- Shalini SharpDirector
- Christine M. KlaskinExecutive Officer
- Charles Evan BallantyneExecutive Officer
- Ozer BaysalExecutive Officer
- Wadih JordanDirector
- Brian CorveseDirector
- Shahzad MalikDirector
- Robert SteinExecutive Officer
- Karen H. ValentineExecutive Officer
- Offering amount
- $500K
- Amount sold
- $500K
- First sale
- Dec 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.4MraisedJan 2016 · 17 investors · BiotechnologyRule 506(b)
▶$7.4MraisedJan 2016 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Karen H. ValentineExecutive Officer
- Timothy R. WrightDirector
- Tom DechaeneDirector
- Shahzad MalikDirector
- Wadih JordanDirector
- Christine M. KlaskinExecutive Officer
- Garo ArmenExecutive Officer, Director
- Brian CorveseDirector
- Charles Evan BallantyneExecutive Officer
- Robert SteinExecutive Officer
- Ozer BaysalExecutive Officer
- Shalini SharpDirector
- Offering amount
- $42.4M
- Amount sold
- $7.4M
- First sale
- Dec 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.1MraisedSep 2015 · 2 investors · BiotechnologyRule 506(b)
▶$2.1MraisedSep 2015 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Wadih JordanDirector
- Shahzad MalikDirector
- Ozer BaysalExecutive Officer
- Karen H. ValentineExecutive Officer
- Christine M. KlaskinExecutive Officer
- Charles Evan BallantyneExecutive Officer
- Garo H. ArmenExecutive Officer, Director
- Robert SteinExecutive Officer
- Tom DechaeneDirector
- Timothy R. WrightDirector
- Shalini SharpDirector
- Brian CorveseDirector
- Offering amount
- $2.1M
- Amount sold
- $2.1M
- First sale
- Sep 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$21.1MraisedMar 2015 · 8 investors · BiotechnologyRule 506(b)
▶$21.1MraisedMar 2015 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Tom DechaeneDirector
- Ozer BaysalExecutive Officer
- Wadih JordanDirector
- Garo ArmenExecutive Officer, Director
- Robert SteinExecutive Officer
- Timothy WrightDirector
- Christine KlaskinExecutive Officer
- Shalini SharpDirector
- Karen ValentineExecutive Officer
- Brian CorveseDirector
- Shahzad MalikDirector
- Offering amount
- $21.1M
- Amount sold
- $21.1M
- First sale
- Feb 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$35MraisedMar 2015 · 1 investors · BiotechnologyRule 506(b)
▶$35MraisedMar 2015 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Timothy WrightDirector
- Karen ValentineExecutive Officer
- Ozer BaysalExecutive Officer
- Garo ArmenExecutive Officer, Director
- Shahzad MalikDirector
- Wadih JordanDirector
- Robert SteinExecutive Officer
- Brian CorveseDirector
- Tom DechaeneDirector
- Christine KlaskinExecutive Officer
- Shalini SharpDirector
- Offering amount
- $35M
- Amount sold
- $35M
- First sale
- Feb 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapBioworld80 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Seeking Alpha80 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Companies competing with Agenus for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 6 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2003 | $188.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2001 | $302.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2000 | $128K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2000 | $100K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
AGEN: Refocused Colorectal Cancer Pipeline And Funding Will Support Future Upsidesimplywall.st · Aug 2026
Agenus (NASDAQ: AGEN) raises $85M and books Zydus gain but flags going concern riskstocktitan.net · Aug 2026Frequently asked questions
- What does Agenus do?
- Agenus is a biotechnology company developing cancer immunotherapies, including its lead investigational combination of botensilimab (an anti-CTLA-4 antibody) and balstilimab (a PD-1 inhibitor), known as BOT+BAL. It provides access to these investigational medicines for cancer patients through pathways such as clinical trials, Named Patient Programs, and compassionate-use programs across multiple countries.
- Who founded Agenus?
- Agenus was founded by Garo Armen.
- Who are Agenus's investors?
- Agenus's investors include Advent Life Sciences, Grazia Equity GmbH, HEALTHCARE ROYALTY PARTNERS, Oberland Capital, Commodore Capital, Invus, Ligand Pharmaceuticals, RA Capital.
- How much funding has Agenus raised?
- Agenus has disclosed $281.2M raised across 9 rounds.
- Where is Agenus headquartered?
- Agenus is headquartered in Lexington, US.